
Peer reviewed version

Link to published version (if available): 10.2106/JBJS.19.00195

Link to publication record in Explore Bristol Research

PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Lippincott, Williams & Wilkins at https://journals.lww.com/jbjsjournal/Abstract/latest/The_Effect_of_Surgical_Approach_on_Outcomes.99918.aspx. Please refer to any applicable terms of use of the publisher.

**University of Bristol - Explore Bristol Research**

**General rights**

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
The Journal of Bone & Joint Surgery

Does surgical approach influence the outcomes following total hip arthroplasty performed for displaced intracapsular hip fractures? An analysis from the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man

--Manuscript Draft--

<table>
<thead>
<tr>
<th>Manuscript Number:</th>
<th>JBJS-D-19-00195R2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Title:</td>
<td>Does surgical approach influence the outcomes following total hip arthroplasty performed for displaced intracapsular hip fractures? An analysis from the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man</td>
</tr>
<tr>
<td>Article Type:</td>
<td>Clinical Research</td>
</tr>
<tr>
<td>Section/Category:</td>
<td>Trauma</td>
</tr>
<tr>
<td>Keywords:</td>
<td>Hip Fracture; total hip arthroplasty; surgical approach; Outcomes; Mortality; revision surgery</td>
</tr>
</tbody>
</table>
| Corresponding Author: | Gulraj S Matharu, BSc (hons), MRCS, MRes  
Royal Orthopaedic Hospital  
Birmingham, UNITED KINGDOM |
| Corresponding Author E-Mail: | gsm@doctors.org.uk |
| Corresponding Author’s Institution: | Royal Orthopaedic Hospital |
| First Author:     | Gulraj S Matharu, BSc (hons), MRCS, MRes, DPhil |
| Order of Authors (with Contributor Roles): | Gulraj S Matharu, BSc (hons), MRCS, MRes, DPhil (Conceptualization; Formal analysis; Investigation; Methodology; Writing – original draft)  
Andrew Judge (Conceptualization; Formal analysis; Methodology; Writing – review & editing)  
Kevin Deere (Formal analysis; Methodology; Writing – review & editing)  
Ashley W Blom (Conceptualization; Investigation; Methodology; Writing – review & editing)  
Mike R Reed (Conceptualization; Investigation; Methodology; Writing – review & editing)  
Michael R Whitehouse (Conceptualization; Investigation; Methodology; Writing – review & editing) |
| Additional Information: |  |

<table>
<thead>
<tr>
<th>Question</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is this a clinical trial? This is defined as any clinical research in which patients were randomized into two treatment groups OR in which patients were followed prospectively to compare two different treatments.</td>
<td>No</td>
</tr>
<tr>
<td>Was this study NIH funded?</td>
<td>No</td>
</tr>
</tbody>
</table>
Abstract:

Background

Studies suggest the anterolateral approach is preferable to the posterior approach when performing total hip arthroplasty (THA) for displaced intracapsular hip fractures, due to a perceived reduced risk of reoperations and dislocations. However, this comes from small studies with short follow-up. We determined whether surgical approach in THAs performed for hip fracture effects revision-free survival, patient survival, and intraoperative complications.

Methods

We retrospectively analysed all primary THAs for hip fractures between 2003-2015 recorded in the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man. The two surgical approach groups (posterior versus anterolateral) were matched for patient and surgical confounding factors using propensity scores, with outcomes compared using regression modelling. Outcomes were 5-year revision-free survival (all-cause, revision for dislocation/subluxation, revision for periprosthetic fracture), patient survival (30-days, 1-year, and 5-years), and intraoperative complications.

Results

After matching, 14,536 THAs were studied (7,268 in each group). Five-year cumulative revision-free survival rates were similar (posterior 97.3% vs. anterolateral 97.4%; sub-hazard ratio (SHR) 1.15 (95% CI 0.93-1.42)). Five-year revision-free survival rates from dislocation (SHR=1.28 (CI=0.89-1.84)) and from revision for periprosthetic fracture (SHR=1.03 (CI=0.68-1.56)) were also comparable. Thirty-day patient survival was significantly higher with a posterior approach (99.5% vs. 98.8%; hazard ratio (HR)=0.44 (CI=0.30-0.64)), persisting at 1-year (HR=0.73 (CI=0.64-0.84)) and 5-years (HR=0.87 (CI=0.81-0.94)). The posterior approach had a lower risk of intraoperative complications (odds ratio=0.59 (CI=0.45-0.78)).

Conclusions

In THA for hip fractures, the posterior approach had a similar risk of revision, a lower
risk of mortality and intraoperative complications compared with the anterolateral approach. We propose that the posterior approach is as safe as the anterolateral approach when performing THA for hip fractures, and either approach may be used according to surgeon preference.
Response to reviewer comments for JBJS-D-19-00195R1 “Does surgical approach influence the outcomes following total hip arthroplasty performed for displaced intracapsular hip fractures? An analysis from the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man”

We would like to thank the editor and the reviewer for their comments, which we feel have helped us to improve our paper.

Please note all changes to the main manuscript text have been highlighted in bold text.

Responses to editor and reviewers’ comments are also in bold text below.

Deputy Editor Comments

Dear Mr. Matharu:

Thank you for revising your manuscript. The manuscript is much improved as a result of your revisions.

I have included a short comment from Reviewer #3 regarding your conclusion. I agree with Reviewer #3 that your conclusion is too strong for the data that you have presented – I don’t think you can state with such certainty that one approach is superior to another. I would ask that you modify the comments that you have made in your conclusion to reflect that all approaches largely speaking are safe and you cannot reliably recommend one over the other. Please consider these comments and, if you feel that they can be addressed in a major revision of the manuscript, please submit your revised manuscript along with a response letter that contains a point-by-point response to the comments. Additionally, all corresponding changes to the text should be in bold. The due date for revision will be Aug 02 2019 11:59PM.

In light of the editor and reviewer comments we have altered our conclusion of the abstract (2nd sentence) and the conclusion of the main text accordingly (2nd sentence). When I get your revised manuscript back with those changes we will send it to the Methodology & Statistics Editor for a final assessment.

Yours truly,
James P. Waddell, C.M., MD, FRCSC
Deputy Editor

The Journal of Bone & Joint Surgery

Reviewer 3:
Conclusion slightly too rigid as to "preference" and "should". Possibly preference is okay but working at "should" - is a sweeping generalization a problem in light of other literature. Editor to decide.

We have altered our conclusion of the abstract (2nd sentence) and the conclusion of the main text accordingly (2nd sentence).
Does surgical approach influence the outcomes following total hip arthroplasty performed for displaced intracapsular hip fractures? An analysis from the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man

Gulraj S Matharu (DPhil),¹ Andrew Judge (PhD)¹,², Kevin Deere (MSc)¹,
Ashley W Blom (PhD),¹,² Mike R Reed (MD),³ Michael R Whitehouse (PhD)¹,²

1. Musculoskeletal Research Unit, Bristol Medical School, University of Bristol, Level 1 Learning and Research Building, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB, United Kingdom
2. National Institute for Health Research Bristol Biomedical Research Centre, University of Bristol, United Kingdom
3. Northumbria Healthcare NHS Foundation Trust, Department of Trauma and Orthopaedics, Wansbeck General Hospital, Woodhorn Lane, NE63 9JJ, United Kingdom

Corresponding author:
Name: Gulraj Matharu Email: gulraj.matharu@bristol.ac.uk
Tel: +44 (0) 7949 921545 Address: Musculoskeletal Research Unit, Bristol Medical School, University of Bristol, Level 1 Learning and Research Building, Southmead Hospital, Westbury-on-Trym Bristol, BS10 5NB, United Kingdom

Co-corresponding author
Name: Prof Mike Reed Email: mike.reed@nhs.net
Does surgical approach influence the outcomes following total hip arthroplasty performed for displaced intracapsular hip fractures? An analysis from the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man

Abstract

Background
Studies suggest the anterolateral approach is preferable to the posterior approach when performing total hip arthroplasty (THA) for displaced intracapsular hip fractures, due to a perceived reduced risk of reoperations and dislocations. However, this comes from small studies with short follow-up. We determined whether surgical approach in THAs performed for hip fracture effects revision-free survival, patient survival, and intraoperative complications.

Methods
We retrospectively analysed all primary THAs for hip fractures between 2003-2015 recorded in the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man. The two surgical approach groups (posterior versus anterolateral) were matched for patient and surgical confounding factors using propensity scores, with outcomes compared using regression modelling. Outcomes were 5-year revision-free survival (all-cause, revision for dislocation/subluxation, revision for periprosthetic fracture), patient survival (30-days, 1-year, and 5-years), and intraoperative complications.
Results

After matching, 14,536 THAs were studied (7,268 in each group). Five-year cumulative revision-free survival rates were similar (posterior 97.3% vs. anterolateral 97.4%; sub-hazard ratio (SHR) 1.15 (95% CI 0.93-1.42)). Five-year revision-free survival rates from dislocation (SHR=1.28 (CI=0.89-1.84)) and from revision for periprosthetic fracture (SHR=1.03 (CI=0.68-1.56)) were also comparable. Thirty-day patient survival was significantly higher with a posterior approach (99.5% vs. 98.8%; hazard ratio (HR)=0.44 (CI=0.30-0.64)), persisting at 1-year (HR=0.73 (CI=0.64-0.84)) and 5-years (HR=0.87 (CI=0.81-0.94)). The posterior approach had a lower risk of intraoperative complications (odds ratio=0.59 (CI=0.45-0.78)).

Conclusions

In THA for hip fractures, the posterior approach had a similar risk of revision, a lower risk of mortality and intraoperative complications compared with the anterolateral approach. We propose that the posterior approach is as safe as the anterolateral approach when performing THA for hip fractures, and either approach may be used according to surgeon preference.

Level of Evidence

Prognostic Level III
Introduction

Hip fractures are common in elderly patients (≥60 years), and associated with significant mortality, morbidity, and healthcare costs. In the US, over 300,000 hip fractures occur annually, with increasing incidence. Displaced intracapsular hip fractures are the commonest type (48%), and are treated using hemiarthroplasty or total hip arthroplasty (THA). THA has lower reoperation rates and improved functional outcomes. The National Institute for Health and Care Excellence recommends that for displaced intracapsular hip fractures, THA should be performed in independently mobile patients with no cognitive impairment who are medically fit for anaesthesia/surgery. However, a recent analysis of the UK National Hip Fracture Database (NHFD) involving 114,119 hip fractures reported only 32% of eligible patients received THA. Strategies have now been implemented to improve this; therefore we expect the number of THAs for hip fractures will increase.

Two main surgical approaches are used for THA, posterior or anterolateral. In the elective setting, there is no conclusive evidence to recommend one approach over the other in terms of reoperation rates or functional outcomes, although the posterior approach has been associated with lower 90-day mortality. Surgeons therefore decide which approach to use, largely dictated by training and preference. Few studies have assessed the effect of approach on outcomes following THA for hip fracture. Current data suggests the anterolateral approach is preferable as it is associated with a reduced risk of reoperations and dislocations. However, these studies were small (171-1,412 THAs) with short-term follow-up (3-24 months).

We assessed the effect of surgical approach on outcomes following THA performed for hip fractures.
Methods

A retrospective analysis of prospectively collected observational data was performed using data from the National Joint Registry (NJR) for England, Wales, Northern Ireland and the Isle of Man. It was established in April 2003 and is the world’s largest arthroplasty registry. Preoperatively patients consent for their details to be recorded within the NJR and data linkage to be performed, with 92% providing consent. In the emergency setting, such as hip fracture, consent is taken whilst the patient rehabilitates in hospital. Operating teams complete data capture forms after performing primary or revision arthroplasty, which are entered onto the database.

Independent validation studies have reported data completion and accuracy are excellent for primary and revision procedures within the NJR. Unique patient identifiers permit linkage of primary and revision procedures where components are removed, added or exchanged. The NJR achieves high levels of procedure linkage (94%). The NJR database was linked to the Office for National Statistics (ONS) database (records all-cause mortality).

We used anonymized patient data from the NJR for stemmed primary THAs performed for hip fractures between 1st April 2003 and 31st December 2015 (n=18,887; Table 1), which allowed at least 1-year of follow-up. The exposure was the surgical approach for THA, namely posterior or anterolateral (anterolateral, lateral, and Hardinge). For each procedure the NJR collects data on patient demographics and the surgery performed. Data collected includes age, sex, body mass index (BMI), date of surgery, American Society of Anesthesiologists (ASA) grade, anesthetic, surgeon grade, and components implanted (fixation, bearing surface, femoral head size).
Outcomes of interest were revision-free survival (at 5-years), patient survival (at 30-days, 1-year and 5-years), and intraoperative complications (calcar crack, pelvic and/or femoral shaft penetration, trochanteric and/or femoral shaft fracture, and other complications). **Revision-free** survival was examined using three **survival** endpoints: free from all-cause revision (i.e. no THA component added, removed and/or exchanged), free from revision for dislocation/subluxation, and free from revision for periprosthetic fracture.

**Statistical analysis**

We controlled for potential patient and surgical confounding factors using propensity score matching. Posterior approach THAs were matched by propensity scores to anterolateral approach THAs (one-to-one ratio). We matched on the logit of the propensity score with a 0.02 standard deviation caliper width. Greedy matching (match to nearest neighbor) without replacement was used (each hip matched only once), which has demonstrated superior performance for estimating treatment effects.

Approach groups were matched for age, sex, year of surgery, bilateral THA for hip fracture, ASA grade, anesthetic, surgeon grade, THA fixation, bearing surface, and femoral head size. Groups were not matched on body mass index because of missing data (81% missing as difficult to measure in fracture patients). Missing BMI data is a limitation of NJR based studies with previous work showing no effect on outcomes following imputation.

Propensity scores were generated using logistic regression, with scores representing the probability (from zero to one) that a posterior approach was used. The two groups were matched based on individual propensity scores. The standardised mean difference (SMD) was
used to measure covariate imbalance before and after matching.\textsuperscript{30, 31} An SMD of 0.10 or more for any covariate following matching was suggestive of residual covariate imbalance.\textsuperscript{25, 30}

Cumulative \textbf{revision-free} and patient survival rates were determined using Kaplan-Meier estimates. Patients who were alive with a THA not requiring revision were censored on the study end date (31\textsuperscript{st} December 2016). \textbf{Revision-free} survival rates were compared between approach groups using Fine and Gray competing risk regression modelling, which accounted for mortality risk. Patient survival rates were compared between the groups using Cox regression, \textbf{whilst} the risk of intraoperative complications was compared using logistic regression. Proportional sub-hazards and hazards assumptions were assessed and satisfied for all analyses. To account for clustering within the matched cohort, a robust variance estimator was used in the \textbf{revision-free} and patient survival regression models, with a conditional logistic regression model used for assessing intraoperative complications.\textsuperscript{32} Univariable regression models were assessed in the matched cohort. As a sensitivity analysis, univariable regression models were also assessed in the original unmatched cohort. P-values of \textless 0.05 were considered significant, with 95\% confidence intervals (CI) also used.

\textbf{Source of funding}

National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals Bristol NHS Foundation Trust and University of Bristol.
Results

In the unmatched cohort (n=18,887; Table 1) six covariates had imbalance between groups (SMDs≥0.10). After matching there were 14,536 cases available for analysis (7,268 per group), with no covariate imbalance suggesting good matching performance (Table 1). All analyses are based on the matched cohort unless stated. The mean follow-up period for surviving patients not undergoing revision was 4.0-years (range 1.0-13.0), and similar between groups (mean 3.9-years posterior and 4.0-years anterolateral).

Revision-free survival

Overall 350 THAs were revised at a mean postoperative time of 1.8 years (range 0 days to 12.1 years). The commonest reasons for revision were dislocation/subluxation (n=118; 33.7% of all revisions), periprosthetic fracture (n=84; 24.0%), aseptic loosening (n=55; 15.7%), and infection (n=53; 15.1%) (Table 2).

The 5-year cumulative revision-free survival rates were similar between the approach groups (posterior 97.3% vs. anterolateral 97.4%; sub-hazard ratio (SHR) 1.15 (CI 0.93-1.42); p=0.185) (Table 3 and Figure 1). The 5-year cumulative revision-free survival rates for dislocation were similar (98.9% vs. 99.2%; SHR 1.28 (CI 0.89-1.84); p=0.188). The 5-year cumulative revision-free survival rates for periprosthetic fracture were similar (99.4% vs. 99.4%; SHR 1.03 (CI 0.68-1.56); p=0.879).

Patient survival

Overall there were 2,885 deaths at a mean of 2.8 years (range 0 days to 12.2 years) from surgery. Thirty-day cumulative patient survival rates were significantly higher in THAs implanted using a posterior approach (99.5% vs. 98.8%; hazard ratio (HR)=0.44 (CI=0.30-
0.64); p<0.001) (Table 3). These observations persisted at 1-year (HR=0.73 (CI=0.64-0.84); p<0.001) and 5-years (HR=0.87 (CI=0.81-0.94); p<0.001) (Table 3 and Figure 2).

Intraoperative complications

Overall the risk of intraoperative complications was 1.5% (n=224). The commonest complications were fractures of the calcar (n=80; 36% of all intraoperative complications), trochanter (n=61; 27%) and pelvis (n=48; 21%). The risk of intraoperative complications with the posterior approach was 1.2% (n=84) compared with 1.9% (n=140) with the anterolateral approach. The posterior approach had a significantly lower risk of intraoperative complications (odds ratio=0.59 (CI=0.45-0.78); p<0.001).

Sensitivity analyses

In the unmatched cohort, the same findings were observed as in the matched cohort for revision-free survival rates, 30-day patient survival rates, and the risk of intraoperative complications (Appendix). However in the unmatched cohort, patient survival rates were similar between the approach groups at 1-year and 5-years postoperatively.
Discussion

This is the largest study assessing the influence of surgical approach on outcomes following THA for hip fracture. We observed that the posterior approach was associated with a reduced risk of mortality and intraoperative complications compared with the anterolateral approach. The posterior approach did not confer any increased risk of revision surgery, including specifically for dislocation and periprosthetic fracture.

Our observations regarding similar revision rates between the two approach groups were seen in both the matched and unmatched cohorts. These findings were contrary to previous studies, which have suggested the anterolateral approach is associated with a reduced risk of reoperations and dislocations.\textsuperscript{16-21} Some of these differences may relate to study design. Previous studies have been small (most with less than 1,000 THAs) with short-term follow-up and few outcome events. These previous analyses may have been underpowered for the outcomes assessed. Furthermore, previous studies have not matched the two approach groups for known risk factors for dislocation and fracture, such as age, sex, implant fixation and femoral head size.\textsuperscript{33, 34} For example in the unmatched cohort, larger femoral head sizes (above 36mm) were more commonly used in the posterior compared with the anterolateral approach (Table 1: 26.4\% vs. 16.6\%), which may reduce the risk of revision for dislocation. However after matching, the use of large heads were similar between groups (posterior 19.0\% vs. anterolateral 18.5\%). Therefore the current matched analysis reduced the risk of confounding, which improves the validity of our findings in a large population based study.

The posterior approach is the most commonly used approach when elective THAs are performed for arthritis.\textsuperscript{22, 35} The present unmatched cohort from the NJR also demonstrates
that it is the most frequently used approach for THAs performed for hip fracture in this setting (56.4%). It has been suggested that surgeons will achieve the best results following THAs for hip fracture if they use the approach with which they are most familiar. Early observations from the NJR of 1,302 THAs performed for hip fracture found a higher revision rate with the posterior approach (3.5% vs. 1.3% at 3 years), which coincides with a time when the posterior approach was used less frequently for elective THA. The increased use of the posterior approach for THA may also explain the reduced risk (41%) of intraoperative complications, namely fractures, observed.

Hip fracture surgery is associated with high mortality rates, which are much higher than elective THA. The NHFD reported overall 30-day mortality rates in all hip fractures of 6.7%, with a secular decline. We observed a much lower 30-day mortality rate for all THAs for hip fractures (0.9%), reflecting selection bias of medically fit and independently mobile patients for THA. Despite this low mortality rate, we still observed a significantly reduced risk (56%) of 30-day mortality when using the posterior compared with the anterolateral approach. In the matched cohort, this improved patient survivorship waned with time, but had not completely dissipated by 5-years postoperatively. Our analysis in the unmatched cohort confirmed a significantly reduced risk of 30-day mortality with the posterior approach; therefore supporting a real effect of surgical approach on mortality at least in the short-term. We are unaware of any other large studies assessing the effect of surgical approach on mortality following THA for hip fracture. A study of 409,096 elective THAs from the NJR demonstrated a significantly lower 90-day mortality rate in procedures performed using a posterior approach. These observations parallel the current observations in hip fracture patients. The posterior approach is a more muscle sparing approach compared with the anterolateral approach and associated with less bleeding. Problems therefore seen more
commonly following the anterolateral approach include nerve injury,\textsuperscript{38} reduced muscle strength,\textsuperscript{39} and limping.\textsuperscript{12} These problems invariably influence patient mobility, especially in the early postoperative phase when the mortality risk will be high. Our previous exploration of mortality in elective THA demonstrated lower all-cause and respiratory mortality with the posterior approach, most likely related to improved mobility, an effect likely to be more marked in a frail population.\textsuperscript{40} We therefore suspect these factors explain the lower mortality rates observed, especially in the short-term, when using the posterior approach.

Study strengths include using linked data from the world’s largest arthroplasty registry. Assessment of an unselected nationwide population reduces the risk of sampling bias, improving validity and generalisability. Although randomised controlled trials would be ideal for assessing this research question, such trials would be impractical as huge patient numbers would be required to power the study given the prevalence of revision, mortality, and intraoperative complications were relatively low.\textsuperscript{41} Therefore large cohort studies ensure adequate statistical power and reduce the risk of overfitting the regression models; thus this design is ideal for our proposed research question. Robust statistical methods were used in this study. This included studying a large matched comparison group, thus reducing any effects from other potential confounding factors.\textsuperscript{27} Finally, studies validating NJR data have observed that, when procedures were captured within the NJR, the data completion and accuracy were excellent.\textsuperscript{23, 24}

Recognised limitations include using observational data, so causality cannot be inferred. THA revision rates can be underestimated in the NJR,\textsuperscript{23, 24} although there is no reason to suspect any underreporting would differ between the approach groups. The NJR does not
collect data on patient reported outcome measures (PROMs) **following hip fracture**, non-revision procedures (i.e. wound washouts, fixation of fractures, and closed reductions of dislocated hips), **or complications not requiring further surgery** (i.e. conservatively treated dislocations, fractures, and infections), which are all important to consider when comparing approaches. **Therefore we cannot estimate the true incidence of dislocation, periprosthetic fracture, and infection after THA for hip fracture**, only those undergoing **revision**. Linkage has been possible for NJR and PROMs data for elective THA, which has favoured the posterior approach.\(^{42}\)

Despite matching there is potential for residual confounding. **We could only match for covariates where data is collected and available in the NJR, so it is not possible to have matched for specific serious medical comorbidities (e.g. renal or cardiac failure), or conditions where patients may be at increased risk of THA dislocation (e.g. Parkinson’s disease or cerebral palsy), which may have influenced approach selection and the findings.** However when significant findings were identified, the observed effect sizes were large; therefore it is unlikely any unmeasured factors would have been large enough to change the direction of the effect sizes. Matching may have also reduced the generalisability of the study findings, although similar findings were observed when the analyses were repeated in the original unmatched cohort. **In addition, our findings may not apply in countries using different techniques.** For example about 70% of femoral stems were cemented in this study. Given cemented stems have a lower risk of fracture compared with cementless stems, **our findings may not apply in regions performing predominantly cementless stem THA for hip fracture.**
Although the follow-up period was short (mean 4 years), the majority of complications attributable to surgical approach would be expected to occur in this period. Matching for BMI would have strengthened the findings, but due to low data completion for this variable in hip fractures, matching could not be undertaken. Reassuringly the available BMI data was similar between the two approach groups before and after matching. The NJR does not collect data on the specific details of how each approach was performed. Therefore we are limited by not having data on parameters, which may influence the outcomes and study findings when considering surgical approach. These include what specific approach techniques were used (i.e. anterolateral approach has many variants), the repair performed (none, capsular, short external rotators, abductors, and whether repairs were soft-tissue or intraosseous), intraoperative blood loss, and surgical time. Furthermore it was not possible to explore the effect of the increasingly popular direct anterior approach in this study given low numbers and variable collection over the life of the NJR.

Conclusions
This large nationwide study observed that in patients undergoing THA for hip fracture, the posterior approach had a similar risk of revision surgery, a lower risk of mortality and intraoperative complications compared with the anterolateral approach. We therefore propose that the posterior approach is as safe as the anterolateral approach when performing THA for hip fractures, and either approach may be used according to surgeon preference.
References


33. Hailer NP, Weiss RJ, Stark A, Karrholm J. The risk of revision due to dislocation after total hip arthroplasty depends on surgical approach, femoral head size, sex, and primary


Figure Legends

**Figure 1** Cumulative *revision-free* survival rate free from all-causes following primary total hip arthroplasty (THA) performed for hip fracture by surgical approach. Shaded area represents the respective upper and lower limits of the 95% confidence interval (CI).

**Figure 2** Cumulative patient survival rate following primary total hip arthroplasty (THA) performed for hip fracture by surgical approach. Shaded area represents the respective upper and lower limits of the 95% confidence interval (CI).
Acknowledgements

We thank the patients and staff of all the hospitals who have contributed data to the National Joint Registry. We are grateful to the Healthcare Quality Improvement Partnership, the National Joint Registry Steering Committee, and staff at the National Joint Registry for facilitating this work. The views expressed represent those of the authors and do not necessarily reflect those of the National Joint Registry Steering Committee or Healthcare Quality Improvement Partnership, who do not vouch for how the information is presented.

Competing Interests

We have read the journal's policy and the authors of this manuscript have the following competing interests: GSM has received financial support for other research work from Arthritis Research UK, The Orthopaedics Trust, The Royal College of Surgeons of England, and The Royal Orthopaedic Hospital Hip Research and Education Charitable Fund. GSM has also received personal fees for undertaking medicolegal work for Leigh Day. AJ has received consultancy, lecture fees and honoraria from Servier, UK Renal Registry, Oxford Craniofacial Unit, IDIAP Jordi Gol, Freshfields Bruckhaus Deringer, is a member of the Data Safety and Monitoring Board (which involved receipt of fees) from Anthera Pharmaceuticals, INC., and received consortium research grants from ROCHE. KW has no relevant conflicts. AWB has no relevant conflicts of interest. MRR has received grant funding or lecture fees from the Health Foundation, Stryker, Zimmer Biomet, Heraeus Medical, 3M healthcare, Vifor Pharma and Schuelke. MRW is a co-applicant on a grant funded by Stryker investigating the outcome of a total knee replacement manufactured by Stryker. MRW also carries out basic science teaching on behalf of Heraeus and DePuy for which his employer receives payment at market rates.
Financial Disclosure

This study was supported by the NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol (AJ, AB, MW). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. This study was supported by funding from Healthcare Quality Improvement Partnership and the National Joint Registry. Posts of authors of this work are part funded by a grant from the National Joint Registry to conduct statistical analysis for the National Joint Registry. The sponsor of the study had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. GM, KD, and AJ had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. MRW had final responsibility for manuscript submission.
### Table 1: Patient and surgical factors before and after propensity score matching

<table>
<thead>
<tr>
<th>Covariate</th>
<th>Unmatched cohort</th>
<th>Matched cohort</th>
<th>SMD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All primary THAs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n=18,887) (100%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antero-lateral approach</strong> (n=8,226) (43.6%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Posterior approach</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n=10,661) (56.4%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SMD</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>All primary THAs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n=14,536) (100%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antero-lateral approach</strong> (n=7,268) (50%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Posterior approach</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n=7,268) (50%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SMD</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Covariate</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female vs. male</td>
<td>13,844 (73.3)</td>
<td>10,734 (73.8)</td>
<td>0.006</td>
</tr>
<tr>
<td>Age at primary (yr)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>71.6 (10.0)</td>
<td>71.6 (10.0)</td>
<td>0.006</td>
</tr>
<tr>
<td>BMI (kg/m²) *</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>26.0 (5.1)</td>
<td>25.9 (5.1)</td>
<td>0.099</td>
</tr>
<tr>
<td>Bilateral hips</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>421 (2.2)</td>
<td>325 (2.2)</td>
<td>0.001</td>
</tr>
<tr>
<td>Primary year</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2003-2012</td>
<td>8,534 (45.2)</td>
<td>6,772 (46.6)</td>
<td>0.009</td>
</tr>
<tr>
<td>2013-2015</td>
<td>10,353 (54.8)</td>
<td>7,764 (53.4)</td>
<td>0.009</td>
</tr>
<tr>
<td>Primary ASA grade</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>1,975 (10.5)</td>
<td>1,562 (10.8)</td>
<td>0.026</td>
</tr>
<tr>
<td>2</td>
<td>11,563 (61.2)</td>
<td>8,968 (56.4)</td>
<td>0.004</td>
</tr>
<tr>
<td>3 or above</td>
<td>5,349 (28.3)</td>
<td>4,006 (25.7)</td>
<td>0.014</td>
</tr>
<tr>
<td>Anesthetic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General</td>
<td>10,187 (53.9)</td>
<td>7,652 (52.6)</td>
<td>0.010</td>
</tr>
<tr>
<td>Spinal</td>
<td>9,818 (52.0)</td>
<td>7,491 (51.5)</td>
<td>0.004</td>
</tr>
<tr>
<td>Epidural</td>
<td>985 (5.2)</td>
<td>764 (5.3)</td>
<td>0.005</td>
</tr>
<tr>
<td>Nerve block</td>
<td>2,507 (13.3)</td>
<td>1,857 (12.8)</td>
<td>0.014</td>
</tr>
<tr>
<td>Surgeon grade</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consultant vs. other</td>
<td>13,933 (73.8)</td>
<td>10,617 (73.0)</td>
<td>0.011</td>
</tr>
<tr>
<td>Fixation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cemented</td>
<td>8,274 (43.8)</td>
<td>6,798 (46.8)</td>
<td>0.014</td>
</tr>
<tr>
<td>Uncemented</td>
<td>4,646 (24.6)</td>
<td>3,732 (25.7)</td>
<td>0.007</td>
</tr>
<tr>
<td>Hybrid</td>
<td>5,449 (28.9)</td>
<td>3,620 (24.9)</td>
<td>0.014</td>
</tr>
<tr>
<td>Reverse hybrid</td>
<td>518 (2.7)</td>
<td>386 (2.7)</td>
<td>0.004</td>
</tr>
<tr>
<td>Femoral head size</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Under 32 mm</td>
<td>8,551 (45.3)</td>
<td>6,977 (48.0)</td>
<td>0.014</td>
</tr>
<tr>
<td>32mm</td>
<td>6,155 (32.6)</td>
<td>4,834 (33.3)</td>
<td>0.014</td>
</tr>
<tr>
<td>36 mm and above</td>
<td>4,181 (22.1)</td>
<td>2,725 (18.8)</td>
<td>0.014</td>
</tr>
<tr>
<td>Bearing surface</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MoP</td>
<td>14,851 (78.6)</td>
<td>11,664 (78.2)</td>
<td>0.007</td>
</tr>
<tr>
<td>CoP</td>
<td>2,206 (11.7)</td>
<td>1,450 (10.0)</td>
<td>0.007</td>
</tr>
<tr>
<td>CoC</td>
<td>1,282 (6.8)</td>
<td>1,010 (6.9)</td>
<td>0.007</td>
</tr>
<tr>
<td>MoM</td>
<td>548 (2.9)</td>
<td>412 (2.9)</td>
<td>0.007</td>
</tr>
</tbody>
</table>

ASA = American Society of Anesthesiologists; BMI = body mass index; CoC = ceramic-on-ceramic; CoP = ceramic-on-polyethylene; MoM = metal-on-metal; MoP = metal-on-polyethylene; SD = standard deviation; SMD = standardised mean difference; THA = total hip arthroplasty

Values in brackets are percentages unless otherwise indicated.
* Missing data for stated number of hips: BMI (n=15,288 in unmatched cohort, and n=11,783 in matched cohort).

Standardised mean differences of 0.10 or more have been highlighted in bold text
**Table 2** Indications for 350 all-cause revision procedures following primary total hip arthroplasty performed for hip fractures

<table>
<thead>
<tr>
<th>Indication for revision surgery</th>
<th>Number of revised hips with indication (% of all revisions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dislocation / subluxation</td>
<td>118 (33.7)</td>
</tr>
<tr>
<td>Periprosthetic fracture</td>
<td>84 (24.0)</td>
</tr>
<tr>
<td>Aseptic loosening</td>
<td>55 (15.7)</td>
</tr>
<tr>
<td>Infection</td>
<td>53 (15.1)</td>
</tr>
<tr>
<td>Malalignment</td>
<td>36 (10.3)</td>
</tr>
<tr>
<td>Pain</td>
<td>25 (7.1)</td>
</tr>
<tr>
<td>Implant wear</td>
<td>19 (5.4)</td>
</tr>
<tr>
<td>Adverse soft tissue reaction to particulate debris</td>
<td>15 (4.3)</td>
</tr>
<tr>
<td>Other</td>
<td>13 (3.7)</td>
</tr>
<tr>
<td>Lysis</td>
<td>4 (1.1)</td>
</tr>
<tr>
<td>Implant fracture</td>
<td>3 (0.9)</td>
</tr>
<tr>
<td>Head socket mismatch</td>
<td>2 (0.6)</td>
</tr>
</tbody>
</table>

One or more indications may be selected for each hip undergoing revision.

A number of the revision indications (aseptic loosening; implant malalignment; periprosthetic fracture; lysis; implant fracture) can include a problem on either the femoral side or the acetabular side or both sides.
Table 3 Outcomes following primary total hip arthroplasty performed for hip fractures by surgical approach in the matched cohort

<table>
<thead>
<tr>
<th></th>
<th>Whole matched cohort (n=14,536; 100%)</th>
<th>Anterolateral approach (n=7,268; 50%)</th>
<th>Posterior approach (n=7,268; 50%)</th>
<th>Univariable regression analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 year implant survival rate free from all-causes (350 revisions)</td>
<td>97.3% (97.0-97.6)</td>
<td>97.4% (96.9-97.8)</td>
<td>97.3% (96.8-97.7)</td>
<td>SHR = 1.15 (0.93-1.42) p=0.185</td>
</tr>
<tr>
<td>5 year implant survival rate free from dislocation or subluxation (118 revisions)</td>
<td>99.0% (98.8-99.2)</td>
<td>99.2% (98.9-99.4)</td>
<td>98.9% (98.6-99.2)</td>
<td>SHR = 1.28 (0.89-1.84) p=0.188</td>
</tr>
<tr>
<td>5 year implant survival rate free from periprosthetic fracture (84 revisions)</td>
<td>99.4% (99.2-99.5)</td>
<td>99.4% (99.1-99.6)</td>
<td>99.4% (99.1-99.6)</td>
<td>SHR = 1.03 (0.68-1.56) p=0.879</td>
</tr>
<tr>
<td>30 day patient survival (131 deaths)</td>
<td>99.1% (99.0-99.3)</td>
<td>98.8% (98.5-99.0)</td>
<td>99.5% (99.3-99.6)</td>
<td>HR = 0.44 (0.30-0.64) p &lt; 0.001</td>
</tr>
<tr>
<td>1 year patient survival</td>
<td>94.1%</td>
<td>93.3%</td>
<td>95.0%</td>
<td>HR = 0.73</td>
</tr>
<tr>
<td>survival (857 deaths)</td>
<td>(93.7-94.5)</td>
<td>(92.7-93.8)</td>
<td>(94.5-95.5)</td>
<td>(0.64-0.84)</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-------------</td>
<td>-------------</td>
<td>-------------</td>
<td>-------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>p &lt; 0.001</td>
</tr>
<tr>
<td>5 year patient survival (2,321 deaths)</td>
<td>78.0% (77.1-78.9)</td>
<td>76.8% (75.6-78.0)</td>
<td>79.2% (77.9-80.4)</td>
<td>HR = 0.87 (0.81-0.94)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>p &lt; 0.001</td>
</tr>
<tr>
<td>Intraoperative complications (224 complications)</td>
<td>1.5% (n=224)</td>
<td>1.9% (n=140)</td>
<td>1.2% (n=84)</td>
<td>OR = 0.59 (0.45-0.78)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>p &lt; 0.001</td>
</tr>
</tbody>
</table>

HR = hazard ratio; OR = odds ratio; SHR = sub-hazard ratio

Numbers in brackets represent the 95% confidence intervals.

Hazard, odds, and sub-hazard ratios below 1 represent a reduced risk of the specified outcome in the posterior approach group.
Figure 1

THA Implant survival free from all causes at up to 5−years

Survival probability

Follow−up time (years)

95% CI Anterolateral
95% CI Posterior

95% CI

Anterolateral

Posterior
Figure 2

Patient survival at up to 1 year following THA
**Appendix Table** Outcomes following primary total hip arthroplasty performed for hip fractures by surgical approach in the unmatched cohort

<table>
<thead>
<tr>
<th></th>
<th>Whole unmatched cohort (n=18,887; 100%)</th>
<th>Anterolateral approach (n=8,226; 43.6%)</th>
<th>Posterior approach (n=10,661; 56.4%)</th>
<th>Univariable regression analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 year implant survival rate free from all-causes (460 revisions)</td>
<td>97.2% (96.9-97.5)</td>
<td>97.3% (96.8-97.7)</td>
<td>97.1% (96.7-97.5)</td>
<td>SHR = 1.14 (0.95-1.37) p=0.164</td>
</tr>
<tr>
<td>5 year implant survival rate free from dislocation or subluxation (149 revisions)</td>
<td>99.1% (98.9-99.2)</td>
<td>99.1% (98.9-99.4)</td>
<td>99.0% (98.8-99.2)</td>
<td>SHR = 1.18 (0.85-1.63) p=0.326</td>
</tr>
<tr>
<td>5 year implant survival rate free from periprosthetic fracture (115 revisions)</td>
<td>99.3% (99.1-99.4)</td>
<td>99.3% (99.1-99.5)</td>
<td>99.2% (98.9-99.4)</td>
<td>SHR = 1.09 (0.75-1.58) p=0.649</td>
</tr>
<tr>
<td>30 day patient survival (174 deaths)</td>
<td>99.1% (99.0-99.2)</td>
<td>98.9% (98.6-99.1)</td>
<td>99.3% (99.1-99.4)</td>
<td>HR = 0.66 (0.49-0.88) p = 0.005</td>
</tr>
<tr>
<td></td>
<td>1 year patient survival (1,153 deaths)</td>
<td>5 year patient survival (3,101 deaths)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------------</td>
<td>---------------------------------------</td>
<td>--------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 year patient survival</td>
<td>93.9% (93.5-94.2)</td>
<td>77.2% (76.4-77.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 year patient survival</td>
<td>93.6% (93.1-94.2)</td>
<td>77.0% (75.8-78.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>94.1% (93.6-94.5)</td>
<td>77.3% (76.2-78.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HR = 0.93 (0.83-1.04)</td>
<td>HR = 0.98 (0.92-1.05)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>p = 0.197</td>
<td>p = 0.629</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intraoperative complications (286 complications)</td>
<td>1.5% (n=286)</td>
<td>1.9% (n=153)</td>
<td>1.3% (n=133)</td>
<td>OR = 0.67 (0.53-0.84)</td>
</tr>
</tbody>
</table>

HR = hazard ratio; OR = odds ratio; SHR = sub-hazard ratio

Numbers in brackets represent the 95% confidence intervals.

Hazard, odds, and sub-hazard ratios below 1 represent a reduced risk of the specified outcome in the posterior approach group.
CME
We were not asked to prepare these questions as per the decision letter received. Therefore we have not submitted these, but are happy to do so at the next stage or if the paper is accepted for publication.
Copyright Transfer and Author Agreement

In consideration of the review and/or editing by The Journal of Bone and Joint Surgery, Inc. ("JBJS, Inc.") of the following material submitted for publication in a JBJS, Inc. journal:

**JBJS-D-19-00195R1**

Article Tracking #

Does surgical approach influence the outcomes following total hip arthroplasty performed for displaced intrapelvic hip fractures? An analysis from the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man

Article Title (the "Work")

Gulraj Matharu

Corresponding Author Name (the "Author")

Journal of Bone & Joint Surgery

Name of Journal in which Work is to be Published

The Author(s) hereby agree as follows:

**AUTHORS: PLEASE READ CAREFULLY - DO NOT BE GUILTY OF FRAUD OR DUPLICATE SUBMISSION OR PUBLICATION – CONTACT THE EDITORIAL OFFICE BEFORE SIGNING IF YOU HAVE ANY QUESTIONS!**

**NOTE: IF YOU PROVIDE JBJS, INC. WITH VIDEOS ASSOCIATED WITH THE WORK, YOU MUST ALSO COMPLETE AND SIGN JBJS INC.’S VIDEO LICENSE AGREEMENT, WHICH WILL SUPPLEMENT AND BECOME A PART OF THIS AGREEMENT.**

1. a. Each of the Author(s) hereby transfers, assigns and otherwise conveys to JBJS, Inc. all right, title and interest in the Work, including but not limited to any and all copyright(s) therein held by each undersigned Author, together with any rights of each such Author to secure renewals, reissues and extensions of such copyright that may be secured under the laws now or hereafter in force in the United States or in any other country, and any and all rights to bring any court or other action to obtain damages, or injunctive or other relief, in connection with any past, present or future infringement of such copyright(s) or other claim in connection therewith.

   b. **NOTE:** If the article is accepted, the Author(s) shall have the right to elect to have it published according to the open-access model, which provides the public with free unrestricted online access to the article on the corresponding journal’s web site immediately upon publication. If the Author(s) choose the open-access option and pay the applicable article processing charge, the Author(s) will retain the copyright to the article by signing, and uploading to the manuscript submission system, the Wolters Kluwer Open Access License Agreement (the "Open Access License"). The Open Access License grants JBJS, Inc. and its publishing partner Wolters Kluwer the exclusive license to publish the article and to identify themselves as the original publisher. The Open Access License supersedes and replaces Section 1.a of this Agreement and the article is published under the terms of the Creative Commons license designated in the Open Access License.

☐ **UNITED STATES GOVERNMENT EMPLOYEES.** Check this “United States Government Employees” option if the Work or a portion of it has been prepared by any Author (a) who is an employee of the United States

DB3/ 201139582.2
Government and (b) as part of such Author's official employment duties. A work prepared by an employee of the United States Government as part of his or her official duties is called a "work of the United States Government" and is not subject to copyright protection. If it is not prepared as part of the employee's official duties, it may be subject to copyright protection. Therefore, if this "United States Government Employees" option is checked and the work was done as part of the authors' official government duties, the Work will be published with the following legend: "Written work prepared by employees of the Federal Government as part of their official duties is, under the United States Copyright Act, a 'work of the United States Government' for which copyright protection under that Act is not available. As such, copyright protection does not extend to the contributions of employees of the Federal Government prepared as part of their employment."

2. Each of the Author(s) hereby also grants permission to JBJS, Inc. to use such Author's name and likeness in connection with any past, present or future promotional activity by JBJS, Inc., including, but not limited to, promotions for upcoming issues or publications, circulation solicitations, advertising or other publications in connection with JBJS, Inc.

3. Each of the Author(s) hereby warrants, represents and covenants that (i) each of the Author(s) has read and approved the final manuscript or version of the Work; (ii) the Work (or, in the case of JBJS Essential Surgical Techniques Key Procedures video articles only, the Work as a whole) is original; (iii) the Author(s) are the sole owners of all rights of any kind in the Work; (iv) the Work (or, in the case of JBJS Essential Surgical Techniques Key Procedures video articles only, the Work as a whole) has not been previously published and is not under consideration for publication by any person or entity, including electronic publishers, other than JBJS, Inc., and that the Author(s) have not previously transferred, assigned or conveyed, or agreed to transfer, assign or convey, any rights in connection with the Work to any person or entity other than JBJS, Inc.; (v) the Work is not libelous, and the publication of the Work will not infringe upon or misappropriate any copyright, right to privacy, trade secret, proprietary or any other right of any person or other entity; and (vi) any and all necessary approvals, consents, waivers or permissions from third parties in connection with the Work and its publication have been obtained, and that the Author(s) will deliver copies of the same to JBJS, Inc. upon its request. Upon the request of the Editor-in-Chief of JBJS, Inc., the author(s) will provide to JBJS, Inc., in a timely fashion, any or all of the data, facts and information included in or forming the basis for the Work (the "Data"); JBJS, Inc. shall have the right to use (and to permit others to use) the Data in reviewing and/or editing the Work and for any other purpose other than the creation or publication of any other work based exclusively on the Data.

4. To enable Author(s) to comply with the requirements of outside funding bodies, JBJS, Inc. will deposit, into the PubMed Central (PMC) Archive, the final published version of any article identified as requiring such deposit below. PMC will make these articles freely available after an embargo period of 12 months, 6 months (Wellcome Trust only), or immediately upon publication (if the Author(s) choose the open-access option).

Please disclose below if you have received funding for research on which your article is based from any of the following organizations. JBJS, Inc. will not be held responsible for retroactive deposits to PMC if the Author(s) do not identify the funding agency below.

- National Institutes of Health (NIH)
- Wellcome Trust
- Howard Hughes Medical Institute (HHMI)
- Research Councils UK (RCUK)
- Other funding body requiring deposit in repository offering free access after embargo (please list):

5. Each of the Author(s) hereby releases and shall indemnify and hold harmless JBJS, Inc. and its successors, assigns, licensees, officers, directors, employees, and their respective heirs and representatives from and against any and all liabilities, losses, damages and expenses arising out of any claims of any kind that may be asserted against any of them based in whole or in part on any breach of the Author(s)' representations or warranties herein or in the Work or anything contained in the Work, including but not limited to any claims for copyright infringement or violation of any rights of privacy or publicity.

6. Nothing in this Agreement shall constitute any promise by or obligation of JBJS, Inc. to publish the Work, or any portions thereof, at any time in any publication. However, if at any time JBJS, Inc. finally elects not to publish
the Work, JBJS, Inc. shall reconvey to the Author(s), without any representation, warranty or recourse, all of JBJS, Inc.'s rights in the Work under Section 1 hereof at the time of such reconveyance and shall notify the Author(s) of such election and reconveyance; the provisions of section 3 hereof shall survive such reconveyance, and in no event shall JBJS, Inc. have any obligation to return to any Author the manuscript or any other copy(ies) or embodiment(s) of the Work or the Data delivered to JBJS, Inc. by the Author(s) or made by JBJS, Inc.

7. This Copyright Transfer and Author Agreement shall be governed by Massachusetts law. In the unlikely event that the parties hereto are unable amicably to resolve any dispute arising under or in connection with this Agreement, such dispute shall be adjudicated in an appropriate state or federal court in Boston, Massachusetts.

Points 8 and 9 below refer to JBJS Essential Surgical Techniques Key Procedures video articles only:

8. Each of the Author(s) hereby represents, warrants and covenants that the majority of content of the Work is original material, has not been previously published in any form, and is wholly owned by one or more of the Authors, who in turn have the right to grant to JBJS, Inc. the rights and licenses provided herein, and have not entered into or agreed to enter into, and the Work is not subject to, any agreement, arrangement or restriction in conflict or inconsistent with this Author Agreement. Although portions of the Work may not be original to the Work, substantially duplicate publication is strictly prohibited.

9. Notwithstanding any terms in the Publication Agreement to the contrary, Author(s) and JBJS, Inc. agree that Author(s) retain: (i) the rights to reproduce, to distribute, to publicly perform, and to publicly display the Work in any medium for noncommercial purposes, and (ii) the right to prepare derivative works from the Work. For example, Author(s) may make and distribute copies in the course of teaching and research and may post the Work on a personal or departmental academic web site with which the Author(s) have an employment affiliation. Reuse of the Work on any other web site or in any setting affiliated with a professional publisher or with a for-profit corporation or institution of any kind must be authorized by JBJS, Inc. and requires a direct license from JBJS, Inc.; such use may not be authorized by Author(s).

[Signature Page Follows]
NOTE: Handwritten, DocuSigned, digitally verified Adobe, or similar signatures only. Digital signatures must display certification if printed. No other form of electronic or stamped signature is acceptable. Authors are permitted to sign separate forms as long as each form is completed in its entirety.

AUTHOR'S SIGNATURE: Gulraj Matharu
Name (please print): Gulraj Matharu
DATE: 13/06/2019

AUTHOR'S SIGNATURE: [Signature]
Name (please print): Kevin Doere
DATE: 13th June 2019

AUTHOR'S SIGNATURE: [Signature]
Name (please print): Michael Whitehouse
DATE: 17th June 2019

AUTHOR'S SIGNATURE: [Signature]
Name (please print): Paul Scott
DATE: 17th June 2019

AUTHOR'S SIGNATURE: [Signature]
Name (please print): Andrew Judge
DATE: 19th June 2019

AUTHOR'S SIGNATURE: 
Name (please print): 
DATE: 

Upload this signed, completed form to the online submission site or email a scanned copy to editorial@jbjs.org.
Click here to access/download
*Conflict of Interest (see above)*
Col form JBJS Am Deere.pdf
Click here to access/download

**Conflict of Interest (see above)**

Col form JBJS Am Judge.pdf
Click here to access/download
Conflict of Interest (see above)
Col form JBJS Am Reed.pdf
Click here to access/download
Conflict of Interest (see above)
Col form JBJS Am Whitehouse.pdf
Statement regarding need for ethical committee approval

The study was approved by the NJR Research Sub-Committee. As patients provide informed consent for inclusion of their data in the NJR for purposes including research, institutional review board approval was not required.
Click here to access/download
Unblinded Manuscript (Staff Use Only)
Unblinded_Matharu0195R1_MSS.docx